InMed Pharmaceuticals Inc. (INM) is a Biotechnology company in the Healthcare sector, currently trading at $0.71. It has a SharesGrow Score of 47/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Valuation: INM trades at a trailing Price-to-Earnings (P/E) of -0 (S&P 500 average ~25).
Financials: revenue is $5M, +99.4%/yr average growth. Net income is $8M (loss), growing at +18.1%/yr. Net profit margin is -165.1% (negative). Gross margin is 34.5% (-15.4 pp trend).
Balance sheet: total debt is $1M against $18M equity (Debt-to-Equity (D/E) ratio 0.06, conservative). Current ratio is 6.99 (strong liquidity). Debt-to-assets is 4.8%. Total assets: $21M.
Analyst outlook: 2 / 2 analysts rate INM as buy (100%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 90/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 21/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).
